Tecentriq helps the immune system respond more aggressively to cancer, according to the report. The drug is approved for patients with several cancer types, including liver cancer, melanoma, and lung cancer. It was first approved by the FDA in 2016 for bladder cancer.
This is the first time the drug has been approved for children. Approval was granted following a National Cancer Institute trial.
“This approval will make a huge impact in terms of a rare disease that has been particularly challenging to treat,” Alice Chen, MD, of the Developmental Therapeutics Clinic in the U.S. National Cancer Institute’s division of cancer treatment and diagnosis, told U.S. News.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
